This video discusses the evolving landscape of bispecific antibody therapy for relapsed/refractory multiple myeloma (RRMM). The specialists are Ryan Haumschild, PharmD, MS, MBA; hematologist Matthew Pianko, MD; and Anthony Perissinotti, PharmD, BCOP.

Pianko explains that the recent FDA approvals of the bispecific antibodies teclistamab, elranatamab, and talquetamab and have dramatically impacted RRMM treatment. These new, highly effective immunotherapies provide options for RRMM patients who previously had poor choices after their fifth line of therapy. The efficacy and safety balance of bispecific antibodies enables their paradigm-shifting use earlier in myeloma treatment lines in coming years.

Haumschild notes that just 5 years ago, there were limited RRMM options beyond proteasome inhibitors and immunomodulators. Since then, the first B-cell maturation antigen antibody-drug conjugate, chimeric antigen receptor T-cell therapies, and now bispecific antibodies with multiple mechanisms of action have become available. This enables durable response potential across multiple myeloma treatment lines.

In summary, the specialists emphasize how bispecific antibodies are improving outlooks for RRMM patients by providing new, effective treatment options not previously available to this difficult-to-treat population.

Video synopsis is AI-generated and reviewed by Pharmacy Times® editorial staff.